N/A
N=18
Cerebellar tDCS and Balance Training in PwMS
Multiple Sclerosis
Bottom Line
View on ClinicalTrials.gov: NCT04391023 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Score on the Berg Balance Scale — 54.43; 51.43; 54.67; 50.33 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Sham Transcranial Direct Current Stimulation (tDCS) (Device); Balance Training (Behavioral); 2 mA Transcranial Direct Current Stimulation (Device); 4 mA Transcranial Direct Current Stimulation (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Iowa
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Score on the Berg Balance Scale |
54.43; 51.43; 54.67; 50.33; 54.29; 51.17 | — |
| PRIMARY Time to Complete the Timed Up and Go Test (TUG) |
7.81; 7.47; 7.55; 6.99; 7.10; 6.88 | — |
| SECONDARY Time to Complete the Six Minute Walk Test (6MWT) |
464.04; 523.31; 479.33; 542.15; 487.44; 545.03 | — |
| SECONDARY Score on the Fatigue Severity Scale (FSS) |
4.21; 3.62; 3.81; 4.39; 3.60; 3.80 | — |
Summary
Many people with multiple sclerosis (PwMS) have decreased balance and postural control, gait deficits, and a high frequency of falls. High fall rates and mobility impairments pose a significant risk to the independence and quality of life of PwMS. Therefore, effective interventions to improve balance and postural control are urgently needed to decrease the frequency of falls in PwMS. Balance training has been demonstrated to significantly improve postural control and gait in PwMS. One possible treatment modality to amplify the effects of balance training is transcranial direct current stimulation (tDCS), a non-invasive means to increase cortical excitability and potentially prime the brain for task specific learning. The cerebellum plays a vital role in balance and posture and may be an important target structure for tDCS studies seeking to reduce fall risk. Studies have shown that anodal cerebellar tDCS is effective in improving balance control in older adults with high fall risk and patients with chronic stroke. However, the most effective tDCS intensity and the duration of the effects on balance control has not been established. Moreover, no study has combined cerebellar tDCS and balance training to reduce fall risk in PwMS. The purpose of this study is to investigate the effects of cerebellar transcranial direct current stimulation (tDCS) on fall risk in people with relapsing-remitting multiple sclerosis. We will conduct tDCS or SHAM followed by balance training on 4 consecutive days. We will evaluate fall risk with well-established functional tasks, such as the Berg Balance Scale, Timed Up and Go (TUG), the six minute walk test (6MWT), and static posturography.
Prospective participants, men and women with relapsing-remitting MS, will be recruited. To accomplish this study, 30 participants will be randomly assigned into 3 groups (2 mA tDCS, 4 mA tDCS, or SHAM). This study involves 4 daily visits at the Integrative Neurophysiology Lab at the same time of day for each subject and three follow-up visits. The duration of visit 1 will be approximately 2.5 hours and the duration of visits 2-4 will be approximately 1.5 hours. Visit 5, 6, and 7 will be approximately 24 hours, 1 week, and 3 weeks, respectively, after visit 4 and will last approximately 1.5 hours. During tDCS sessions, participants will undergo either Sham, 2 mA, and 4 mA tDCS for 20 minutes followed by balance training.
Eligibility Criteria
Inclusion Criteria
- medically diagnosed with relapsing-remitting multiple sclerosis
- 18-70 years of age
- moderate disability (score of 2-6 on the Patient Determined Disease Scale)
- self-reported differences in function between legs, have fallen within the last year
- able to walk for 6 mins, and not taking any psychoactive medication.
Exclusion Criteria
- relapse within the last 60 days
- have changed disease modifying medications in the last 45 days
- are currently pregnant
- have a concurrent neurological or neuromuscular disease
- have been hospitalized within the last 90 days
- have any contraindications for the tDCS device (i.e., pacemakers or metal implants)
- are unable to understand/sign the consent form.
Data sourced from ClinicalTrials.gov (NCT04391023). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.